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Abstract
Background: Physical activity is recommended for people with peripheral arterial disease (PAD), and can improve
walking capacity and quality of life; and reduce pain, requirement for surgery and cardiovascular events. This trial
will assess the efficacy of a brief behavioral counselling intervention delivered by allied health professionals to
improve physical activity in people with PAD.
Methods: This is a multi-center randomised controlled trial in four cities across Australia. Participants (N = 200) will be
recruited from specialist vascular clinics, general practitioners and research databases and randomised to either the
control or intervention group. Both groups will receive usual medical care, a written PAD management information
sheet including advice to walk, and four individualised contacts from a protocol-trained allied health professional over
3 months (weeks 1, 2, 6, 12). The control group will receive four 15-min telephone calls with general discussion about
PAD symptoms and health and wellbeing. The intervention group will receive behavioral counselling via two 1-h
face-to-face sessions and two 15-min telephone calls. The counselling is based on the 5A framework and will promote
interval walking for 3 × 40 min/week. Assessments will be conducted at baseline, and 4, 12 and 24 months by staff
blinded to participant allocation. Objectively assessed outcomes include physical activity (primary), sedentary behavior,
lower limb body function, walking capacity, cardiorespiratory fitness, event-based claudication index, vascular
interventions, clinical events, cardiovascular function, circulating markers, and anthropometric measures. Self-reported
outcomes include physical activity and sedentary behavior, walking ability, pain severity, and health-related quality of
life. Data will be analysed using an intention-to-treat approach. An economic evaluation will assess whether
embedding the intervention into routine care would likely be value for money. A cost-effectiveness analysis will
estimate change in cost per change in activity indicators due to the intervention, and a cost-utility analysis will assess
change in cost per quality-adjusted life year. A full uncertainty analysis will be undertaken, including a value of
information analysis, to evaluate the economic case for further research.
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Discussion: This trial will evaluate the efficacy and cost-effectiveness of a brief behavioral counselling intervention for a
common cardiovascular disease with significant burden.
Trial registration: ACTRN 12614000592640 Australian New Zealand Clinical Trials Registry. Registration Date 4 June 2014.
Keywords: Exercise, Physical inactivity, Intermittent claudication, Cardiovascular disease, Health counselling, Quality of life,
Cost effectiveness, Biomarkers, Multi-disciplinary, Behavioral health
Background
Peripheral artery disease (PAD) is the narrowing or
blockage of the lower limb arteries usually due to
atherosclerosis and associated thrombosis [1]. This re-
duces blood flow to the limbs, with the most recognised
symptom being leg pain that typically presents during
walking, worsens with exertion, and is relieved by rest
(intermittent claudication: IC). Maximal walking cap-
acity in people with PAD is less than 50 % of that in
age-matched controls, and the functional limitations are
similar to those seen in people with severe heart failure
[2]. People with PAD and IC typically avoid walking and
related activities, which constrains social and role func-
tioning and activities of daily living, and precipitates
poor quality of life and accelerated functional decline
[3]. This, in turn, predisposes them to high health
service utilisation and associated costs [4–11], and
premature mortality [12]. As an indicator of systemic
atherosclerosis, PAD is positively associated with other
cardiovascular diseases, coronary events and stroke [13],
with one meta-analysis suggesting a two-fold increased
risk of mortality, cardiovascular mortality and major
coronary events over 10 years [14]. Coronary heart and
cerebrovascular events account for ~65 % of deaths in
people with PAD, with a two year prospective study sug-
gesting a 70 % increased risk of cardiovascular events
and an 80 % increased risk of death compared to people
with coronary artery disease alone [13].
PAD is a common chronic disease associated with age-
ing. Prevalence has been reported as 8.3 % in people
aged 60–69 years [6], 14.5 % in those aged >70 years
[15] and 40 % of people aged >80 years [16]. The
economic burden of PAD is substantial, as reflected by
expensive vascular surgical interventions aimed at open-
ing or bypassing blocked arteries, and recurring hospita-
lisations [7]. A total of USD$4.37 billion was spent on
PAD-related treatment in 2001, with 88 % for inpatient
care [17]. Prior lower limb revascularisation is associated
with high hospitalisation costs and rates of subsequent
procedures during the following 2 years [7]. Rates of
surgical intervention are increasing dramatically: There
was a 43 % increase between 2000 and 2008 in Australia
which far exceeds the estimated growth in the number
of people with PAD [18]. Such interventions have
limited durability, are expensive to perform and their
value in providing sustained improvement in quality of
life and reducing subsequent morbidity and mortality is
not well established [19, 20]. Given the high prevalence
and burden of PAD, and the large expense and limited
durability of surgical interventions, there is an urgent
need to identify effective, affordable and sustainable
alternative management options.
International guidelines for PAD management recom-
mend exercise [21–24], and typically identify three 40-min
sessions per week of interval walking at maximum
tolerable speed (i.e., moderate pain level with rest periods)
[2, 25]. There is good evidence that supervised exercise is
as effective as surgical procedures in improving walking
ability in patients that have IC [20, 26, 27]. Supervised
exercise programs have been shown to improve walking
capacity, functional mobility, maximal walking distance,
pain symptoms and health-related quality of life; and to
reduce leg pain and cardiovascular risk [20, 28–32].
People with PAD who are physically active have a lower
average annual functional decline than those who are
inactive [33], and a significantly lower five-year mortality
risk [12, 34]. Reduced daily sitting time is associated with
a reduced decline in the six minute walk test [35], with
improvements in walking capacity and physical function-
ing enhancing quality of life in people with PAD with IC
and people without IC [36]. It is estimated that even small
increases in physical activity for people with IC would sig-
nificantly reduce all-cause mortality [12].
However, an international survey found only 30 % of
vascular surgeons had access to supervised exercise pro-
grammes for patients with PAD, and of those who did
have access, many referred less than half their patients
[37]. Patient travel to facility-based supervised exercise
sessions is burdensome, and drop-out rates are often high
[38–40]. Lack of patient and physician awareness of the
role of supervised exercise, and patient barriers of trans-
portation and time contribute to this being an underused
treatment [37, 41, 42]. For those surgeons who do not
have access to refer to supervised exercise programmes,
the usual option is to give brief advice to do walking [37].
However, people with IC have condition-specific barriers
to walking that constrain participation. IC is an intense,
cramping pain in the lower limbs, and some patients
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believe this pain is harmful [43], and have low confidence
in their walking ability [44, 45]. Patients tend to be unclear
about the causes and severity of PAD and the associated
cardiovascular risk [43, 46, 47], and are unaware of walking
recommendations and the mechanisms by which walking
can improve PAD-specific and general health outcomes
[43]. The surgical model of care can precipitate beliefs of
an acute, treatable condition [43] and little personal control
over health outcomes [44, 47]. Illness and treatment beliefs
predict adherence to recommended levels of walking in
people with PAD with very high accuracy [44]. A willing-
ness to persist with activities given the concurrent pain,
and a desire to be functionally competent, are also posi-
tively associated with physical mobility in people with PAD
[45]. Adaptive self-management beliefs are therefore a key
target to enable walking among people with PAD.
Behavioural counselling is a patient-centred approach that
can promote adaptive illness- and exercise-related beliefs
associated with sustained physical activity behaviour change
in people with chronic conditions and cardiovascular risk
[48, 49]. Preliminary evidence indicates that counselling can
improve physical activity in people with PAD. A program
combining weekly cognitive behavioral counselling and walk-
ing sessions demonstrated significant improvements in accel-
erometer assessed physical activity (mean difference 114.7
activity units, 95 % CI 12.82 to 216.5; P= .03); 6-min walk
distance (mean difference 53.5 m, 95 % confidence interval
[CI] 33.2 to 73.8; P < .001); Walking Impairment Question-
naire (WIQ) speed score (mean difference 10.4, 95 % CI 3.4
to 17.4; P= 0.004) and distance score (mean difference 11.1,
95 % CI 3.9 to 18.1; P= 0.003) [50]; and psychosocial indica-
tors of satisfaction with physical functioning, pain acceptance
and social functioning [51] relative to a health education
control group. There were sustained improvements after
12 months in 6-min walk distance (mean difference 34.1 m,
95 % CI, 14.6 to 53.5; P < 0.001) and WIQ speed score (mean
difference 8.8, 95 % CI, 1.6 to 16.1; P < 0.018) [52]. However,
this approach was resource intensive, with weekly sessions
delivered over 6 months. A more brief counselling interven-
tion, involving two 1-h sessions of individualised behavioral
counselling and two follow up telephone calls by a psycho-
logist, demonstrated a significant increase in pain-free walk-
ing distance and daily walking in the intervention versus the
control group (usual care plus non-walking related conversa-
tion during home visits) after four months, with a mean
difference of 1575 pedometer steps/day (95 % CI, 732 to
2419) [53]. At 24 months, the intervention group completed
on average 1630 steps/day (95 % CI, 495 to 2765) more than
the control group, and significantly more participants in the
control group had endovascular or open surgery than in the
intervention group (OR 3.09 95 % CI 1.06 to 9.04; p= 0.037)
[54]. However, as the counselling was delivered by a
psychologist in patients’ homes, the wide scale applicability
of this approach is not known.
Methods/Design
Aim and research questions
The primary aim of this study is to test the efficacy of
brief behavioral counselling, delivered by allied health
professionals, to increase physical activity in people with
PAD. Secondary aims are to examine the effect of the
counselling on functional capacity, revascularisation rate,
clinical events, and resource use; and to perform an
economic evaluation of the counselling intervention
compared to usual care. This fills an important gap in
the literature on PAD clinical management, and will
address the following questions
 can brief behavioural counselling be delivered by
health professionals who are not qualified
psychologists, following training?
 can the brief behavioural counselling be effectively
delivered in a variety of different centres by different
professionals?
 is delivery of the brief behavioural counselling in a
health care setting effective in achieving sustained
physical activity behaviour change?
Design and setting
This is a multicentre, prospective, randomised superiority
trial with two parallel study groups: a control and an inter-
vention group. The trial will be conducted in four cities
across Australia. Study sites will include three specialist
vascular management clinics (Townsville, Brisbane, Perth)
and a University clinic (Sydney).
Management
The trial will be overseen by a Trial Steering Committee
comprising senior vascular investigators from the centers
involved; and experts in trial management, physical activity
behavior change, health economics and exercise physiology.
This will be the main policy and decision-making commit-
tee. Trial coordination will be facilitated by the National
Health and Medical Research Council (NHMRC) funded
National Centre for Research Excellence in Peripheral
Arterial Disease (NCRE-PAD). An independent data man-
agement center (CCRE therapeutics, Monash University)
will provide a computer generated randomisation list. A
study coordinator located at James Cook University will
organise activities across the participating sites; assisting
with local ethics reports and communication with the local
sites (including uniformity of collection and reporting of
data, central randomisation, data storage and processing).
The training, competency assessment, and supervision of
allied health professionals who will deliver the intervention
and control group protocol; and the intervention fidelity
assessment, will be undertaken by a clinical and health
psychologist on the investigatory team (NB).
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Participants
Participants will be recruited from specialist vascular
management clinics at The Townsville Hospital, The
Royal Brisbane and Womens’ Hospital, and Fremantle
Hospital Perth; and from referrals from vascular sur-
geons and general practitioners in Sydney. Participants
will also be recruited from the investigators’ registry of
participants involved in prior research studies who have
agreed to be re-contacted.
People who express an interest in the study will be
screened and enrolled by dedicated assessment staff
either in person or by telephone. Inclusion criteria are
 Diagnosis of PAD by a vascular specialist, including
patient-reported symptoms of IC and/or absence of
lower limb pulses and/or resting ankle brachial
pressure index (ABPI) <0.9 or >1.4 [23];
 Able to walk without assistance of another person
 No current or planned involvement in an organised
exercise trial or program
 No currently planned peripheral vascular
intervention
 Physician confirmed ability to participate in the trial
(i.e. medically stable, able to walk and undertake
physical activity, attend assessments and
comprehend the behavioral counselling). Patients
with severe PAD, such as rest pain, arterial
ulceration or gangrene requiring urgent vascular
intervention will be ineligible.
Exclusion criteria are
 Previous major lower limb amputation such as
above or below knee
 Patients who report doing more than 120 min of
moderate-vigorous structured exercise per week.
Sample size calculation
We hypothesise that over a 4-month period the inter-
vention will increase physical activity by ~50 %, evi-
denced by mean daily step counts of 5000 ± 3400 for
those receiving the counselling intervention compared
to 3300 ± 2200 for those randomised to the control
group. We also hypothesise that these effects will be
maintained at 12 and 24 months post intervention. The
effect size and outcome results estimated are based on
data from a previous trial [54]. We require 62 partici-
pants per group (power 90 %, alpha 0.05, within-subject
between visit correlation 0.6) to detect the hypothesised
increase in physical activity. Allowing for maintenance
of this increase over 24 months, and a drop out of up to
40 %, we require 100 participants per group. We there-
fore will aim to recruit a total of 200 people.
Randomisation
Eligible and consenting individuals who complete the
baseline assessment will be randomly allocated to the con-
trol or intervention group. The allocation sequence will be
computer-generated using a random number sequence and
allocation will occur in block sizes up to 4 and will be
stratified based on ABPI (<0.50, 0.50-0.69, 0.70-0.89, >1.4),
study site, and gender. Allocation is concealed by using a
central randomisation site, and different project staff for
assessment and allocation/intervention delivery. Partici-
pants will be blinded to allocation and the investigators’
hypotheses. Intervention staff will conduct both interven-
tion and control participant contacts, and therefore cannot
be blinded to allocation. They will be instructed not to
disclose the allocation status to either the participants or
assessment staff.
Study protocol and interventions
Recruitment and informed consent will be performed by
project staff not directly involved in the patients’ care.
Potential participants will be approached individually either
by telephone, mail or in person; provided with the study
information; and invited to participate. People who are
screened as eligible and provide written consent will be ran-
domised to either the intervention or control group.
An overview of the participant timeframe is presented
in Fig. 1. Participants in both groups will receive ongoing
medical care from their treating physicians, a written PAD
management information sheet including advice to walk,
and four individualised contacts from an allied health pro-
fessional over 3 months (weeks 1, 2, 6 and 12).
The information sheet provides an overview of PAD
(symptoms, contributing factors) with recommendations to
stop smoking, eat a healthy diet, manage associated condi-
tions such as diabetes and hypertension, and to walk for at
least 40 min three times a week (see Additional file 1). The
information includes instruction to walk until a moderate
level of pain is experienced in the legs, rest until the pain
subsides, and then resume [25].
The allied health professionals are required to be not a
qualified psychologist e.g., nurse, dietician, exercise
physiologist. They will be trained in the control and
intervention protocol by the project psychologist in a
face-to-face meeting (6 h) and given a written manual
and summary participant contact protocol. They are re-
quired to achieve at least 80 % in a competency-based
assessment administered two weeks before commencing
participant contact. The assessment requires verbal de-
scriptions of how they would use the study protocol in re-
sponse to a series of vignettes reflecting participant case
scenarios. During the study period, regular individual tele-
conferences (approximately monthly) will be held between
the allied health staff and the psychologist, to discuss and
problem-solve participant contact issues that arise. To
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assess intervention fidelity, all participant contacts will be
audio recorded and a random selection of sessions (5 %)
will be assessed at study conclusion by the psychologist
against a protocol checklist.
Passive control group
Participants in the control group will receive four 15-min
telephone calls, during which they will be asked open
ended questions about PAD symptoms and general health
and wellbeing (e.g., “How have you been since we last
spoke?, How does your PAD impact on that?”, “How does
that affect your PAD?”) and receive empathic non-specific
responses. Project staff will respond to any specific queries
on PAD management or physical activity by encouraging
participants to read the written PAD management infor-
mation sheet and talk with their treating physician. The
combination of ongoing medical care from treating physi-
cians and a written PAD management information is
intended to represent usual care. The four telephone calls
equalises the frequency of participant contacts between
the control and intervention group. The telephone calls to
control group participants may also mask allocation: par-
ticipants in a no contact control group could determine
allocation to a non-intervention condition.
Active intervention group
Participants in the intervention group will receive two 1-
h face to face behavioral counselling sessions at a univer-
sity or hospital site, and two 15-min telephone sessions.
The counselling protocol used in this trial is based on
the 5A Behavioral Counselling Framework, which is an
evidence-based approach appropriate for physical activ-
ity change in people with chronic conditions and cardio-
vascular risk [55]. The key components of this approach
as applied in this study are:
 Assessment: During the initial session, open ended
questions and clarification probes will be used to
understand patient perceptions of knowledge of
PAD and benefits of walking for PAD, current
walking (frequency and duration), and walking
change (i.e., risks, barriers, enablers, outcome
expectancies, feelings, reasons to change/not
change). Subsequent sessions will focus on current
walking (frequency and duration), and experiences
with walking change (i.e., barriers, enablers, feelings,
outcomes).
 Advice: Verbal advice will be provided to
acknowledge pros and cons of walking, and confirm
understanding and correct misperceptions about
PAD and walking (e.g., PAD causes and
consequences, interpretation of walking pain,
benefits of walking vs. surgery for PAD). Clear and
strong advice will be provided on the need to do
regular walking to manage PAD symptoms and
reduce the risk of serious health events.
 Agree: This will involve collaborative goal setting for
walking i.e. graded goal setting (frequency and duration)
towards recommendations to do three 40-min sessions
per week of interval walking at maximum tolerable
speed (i.e., moderate pain level with rest periods).
 Assistance: Discussion on action planning
(when, where and with whom to do walking),
motivational support (reflecting assessment
information), self-regulation strategies, self-
monitoring, social support, and identifying and
problem solving barriers to walking (promoting
coping, flexibility and control). This information
will be individually tailored to participants’ interests,
opportunities and abilities. The interventionist will
provide praise, highlight effort towards achievement
and gains, and promote adaptive interpretation of
setbacks.
 Arrange: The next contact will be arranged where
appropriate.
Participant retention and withdrawal
Once enrolled, the study site will make every reasonable
effort to follow the participant for the entire study period.
Enrollment





Week 1 15 min telephone call 1 hr face to face
Week 2 15 min telephone call 1 hr face to face
Week 6 15 min telephone call 15 min telephone call
Week 12 15 min telephone call 15 min telephone call
Month 4 Assessment Assessment
Month 12 Assessment Assessment
Month 24 Assessment Assessment
Fig. 1 Study design, participant flow, and assessment schedule
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Study site staff are responsible for implementing local
standard operating procedures to optimise engagement and
minimise attrition. To optimise engagement, contact and
assessment times will be prearranged with participants on
an individual basis. The allied health professionals will
prearrange each contact i.e. the first contact will be
organised at the assessment session, the second contact will
be organised at the first contact etc. Assessment staff will
arrange individualised assessment sessions by telephone.
The allied health professionals will be trained how to
respond to participant ambivalence regarding subse-
quent contacts. The individualised pros and cons of
engagement will be acknowledged and problems with
engagement discussed. The importance of understanding
the diverse spectrum of patient experiences with PAD,
irrespective of patient perceptions of change, will be
indicated. If participants request to discontinue contact,
then participants will be asked if they are willing to
engage with the assessment.
Participant non-attendance at face to face sessions or
for telephone contacts will be followed up by the allied
health professionals. Participant non-attendance at assess-
ment sessions will be followed up by assessment staff.
Non-attendance follow up will be primarily by telephone
with a minimum of ten attempted contacts conducted at
different times of day. Email or a single mail contact may
also be attempted. If participants provide a secondary con-
tact at the initial assessment, this will be used to deter-
mine if the participant is not available due to extenuating
circumstances such as hospitalisation or an adverse event.
Participant non-attendance for control/intervention con-
tacts will be rescheduled as soon as possible after origin-
ally scheduled contact. If this is not possible within a 1–2
week period, then the contact will be identified as not
occurring. The timing of following control/intervention
contacts will be relative to the initial session. The assess-
ment timing will remain constant relative to the first inter-
vention/control contact. Participants who do not attend
one assessment will be invited to attend subsequent
assessment sessions unless they specifically request to
withdraw from the study entirely.
Any physician prescribed or participant initiated
concomitant care is permitted during the trial. Partici-
pants may request to withdraw from the study for any
reason at any time. Should participants choose to
withdraw, all efforts will be made to identify the reason
for withdrawal.
Participant safety
The behavior counselling intervention in this study is
non invasive, low risk and should be well tolerated by
the majority of participants. It is therefore unlikely that
the trial would require stopping because of safety issues.
Participant safety will be monitored through adverse
event reporting via report forms. Adverse events may be
identified by assessment or intervention staff during
contacts, or spontaneously reported by participants.
Definition of adverse events (AE) and serious adverse
events (SAE) will be in line with the Good Clinical Prac-
tice Guidelines (GCPG) [56]. AEs will be defined as any
unfavourable and unintended sign, symptom or disease
that occurs in a participant whether it is considered to
be study-related or not. A SAE will be defined as an
untoward medical occurrence which results in death,
requires inpatient hospitalisation or prolongation of
existing hospitalisation, results in permanent or signifi-
cant disability or is life threatening. All SAEs will be
reported to the relevant Human Research Ethics Com-
mittee (HREC) as soon as possible following identifica-
tion by study centers. The Trial Steering Committee will
monitor SAEs and consider trial termination if events
which appear related to the intervention are identified.
Assessment
Assessments will be conducted at baseline and 4, 12 and
24 months by staff blinded to participant allocation. Each
assessment time point will comprise two facility-based visits
approximately one week apart, the first for 90 min, and the
second for 60 min. At visit 1 (90 min) participants will
provide a blood sample and complete physical activity and
health-related quality of life questionnaires. The Short
Physical Performance Battery (SPPB) and 6-min walk test
(6MWT) will be undertaken. An assessment of ABPI will
be performed. Smoking status, medical and surgical history,
anthropometry, resting heart rate, brachial blood pressure
and ambulatory ability will also be assessed. At the end of
visit 1, participants will be fitted with an activPAL3™
accelerometer, which will be worn for seven consecutive
days. At visit 2 (60 min), participants will return the activ-
PAL3™ accelerometer, and complete additional physical
activity and health related quality of life questionnaires. At
baseline only, the six minute walk test is repeated at visit 2.
Participants will be given the written PAD information
sheet at the end of visit 2. Assessments at 4, 12 and
24 months will also include the recording of any study
defined clinical events since the previous visit.
Primary outcome measures
The primary outcome measure will be daily physical
activity level or walking (i.e. steps per day). This will be
assessed using an activPAL3™ accelerometer (PAL Tech-
nologies Ltd, Glasgow, United Kingdom) which is a
triaxial accelerometer that assesses body position (i.e.
sitting/lying and standing) and walking activity from accel-
erometer recordings at a sampling rate of 20 Hz and sen-
sitivity of ± 2 g [57, 58]. The activPAL3™ unit will be
wrapped in a nitrile sleeve, wrapped in waterproof
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dressing and attached to the right thigh of each participant
using adhesive waterproof dressings (mid-line; 1/3 of the
distance from the inguinal fold to the top of the patella).
Recordings will commence at 06:00 on the following
morning and continue for seven full days whereupon the
activPAL3™ unit will be removed, returned to the investi-
gators and the recording uploaded for analysis. Data are
checked to ensure data has been recorded for the period,
and if not, participants are asked to redo the assessment.
The activPAL3™ has been reported to be reliable and valid
in the assessment of walking, body posture, and sedentary
behavior during free-living activity [57, 59, 60] and when
used with older adults [61] and patients with IC [62].
Secondary outcome measures
In addition to the primary measures of daily physical activity
level and walking (steps/day), other outcome measures from
the activPAL3™ will include daily sedentary (sitting/lying)
time, number of sit-to-stand transitions, and energy expend-
iture (total number of kilocalories per day). Other secondary
outcome measures using objective assessment will include:
 Ambulatory ability and lower body functioning:
This will be assessed using the 6MWT, and the Short
Physical Performance Battery (SPPB) which have
previously been used as outcome measures in PAD
intervention trials [36, 37]. The 6MWTassesses
maximal cardiorespiratory fitness and correlates
strongly with physical activity levels among people
with PAD, and may therefore reflect walking capacity
in everyday life [63]. The SPPB includes three
objective tests of lower body function: A hierarchical
test of standing balance, a timed 4-m walk and 5-
timed repetitive chair stands. The SPPB strongly
predicts loss of ability to walk 400 m [40], and is
predictive of hospitalisation, nursing home admis-
sion and mortality [38, 39, 64]. It is a widely used
and valid measure with established test-retest reli-
ability [65].
 Event-based claudication index (EBCI) which is a
measure of the ratio of walking bouts to upright
time assessed from accelerometer data. Individuals
with PAD have a greater EBCI than age matched
controls, which indicates a fragmented stop/start
walking pattern [47, 62].
 Vascular interventions including endovascular and
surgical lower limb revascularisations and aneurysm
repair.
 Clinical events including cardiovascular events,
amputations, vascular and cardiac surgeries/
interventions, musculoskeletal injury, other injuries
or illness and death determined from patient reviews
and hospital chart reviews, as described elsewhere
[66, 67].
 Circulating pro-thrombotic markers, pro-
inflammatory cytokines, lipids and RNA expression of
circulating cells will be examined at the completion of
the trial using stored blood samples obtained at each
visit. EDTA and citrate plasma, serum and total blood
collected into Paxgene tubes will be obtained at each
assessment time. We have previously established
methods to assess vascular biomarkers with good
repeatability in our central laboratory [68–74].
 Measures of cardiovascular function including heart
rate, blood pressure and ABPI assessed with
standardised protocols as described elsewhere [75].
 Body composition including waist and hip
circumference and body mass index assessed with
standardised protocols as described previously [76].
Secondary measures using self-administered question-
naires include the following.
 Physical activity will be assessed using the
International Physical Activity Questionnaire (IPAQ-
short form) and the Physical Activity Scale for the
Elderly (PASE). The IPAQ has four item groups that
use a past 7 days recall period to ask about frequency
(days/week) and time (mins/day) spent walking for at
least 10 min at a time and in vigorous- and moderate-
intensity activities; and time (mins/day) spent sitting
on a week day. The instrument has good repeatability
and demonstrated validity comparable with other
self-report measures in diverse samples, settings and
countries [77]. The PASE has 11 item groups that use
a past seven days recall period to ask about frequency
(never, 1–2, 3–4, 5–7 days) and average time/day
(<1 h, >1- < 2 h, 2–4 h, >4 h) spent in sitting activities,
walking, light sport or recreational activities, moderate
sport or recreational activities, strenuous sport or
recreational activities, and exercise to increase muscle
strength and endurance; participation (yes/no) in
domestic activities (light housework, heavy house-
work, home repairs, yard work, outdoor gardening
and caring for another); time (hours/week) spent in
volunteer work; and the degree of physical activity
done as part of paid or volunteer work (mainly sitting,
sitting or standing with some walking, walking with
some light-moderate handling, walking and heavy
manual work). Additional items will be used to also
assess distance (number km) of walking and number
of flights of stairs to enable Harvard Alumni Ques-
tionnaire scoring. The PASE has a good correlation
with measures of lower body functioning and the
6MWT [78] and low PASE scores are predictive of
cardiac-related mortality after coronary surgery [79].
 Sedentary behavior will be assessed using the SIT-Q-
7d Questionnaire. This has 18 item groups that use a
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recall of the past seven days to assess average sitting
time for meals (8 categories ranging from none to
>1 h/day); for travel (to and from occupation, as part
of occupation, and other purposes: 13 categories ran-
ging from 0 to >7 h/day); as part of occupation (12
categories ranging from 0 to >8 h/day); for non-
occupational screen-based activities (includes reclin-
ing for watching television, recreational computer use,
playing computer games: 11 categories ranging from 0
to >8 h/day); and other activities (reading, household
tasks, caring for others, hobbies, socialising, listening
to music, other: 11 categories ranging from 0 to >7 h/
day). Items also assess frequency (times/day) of
interrupting sitting time during each of occupation
and watching television; the time of going to sleep
and getting up and duration of napping; and
frequency of consuming each of 11 snack types while
watching television (10 categories ranging from none
to >5 times/day). The questionnaire has acceptable re-
peatability and good criterion validity for total seden-
tary time in otherwise healthy people [80].
 Walking ability will be assessed using the Walking
Impairment Questionnaire (WIQ). This has 21 items
that assess degree of pain and other difficulties (e.g.,
shortness of breath), difficulty in walking for a range
of distances and speeds, and difficulty in climbing
stairs. Responses are recorded on a 5-point Likert
scale with options of none, slight, some, much, and
very/unable. WIQ cut off scores appropriately clas-
sify walking performance (absolute claudication dis-
tance and peak walking time) assessed by a
standardised graded treadmill test in people with
PAD [81], and is a valid tool to detect improvement
in daily walking ability in people with IC [82].
 Health-related quality of life (HRQoL) will be assessed
with the disease-specific Intermittent Claudication
Questionnaire (ICQ) [83] which has 16 items that use
a recall of the past two weeks and a 5-point Likert
scale for responses. Items ask about severity of leg
pain (none to very severe); the extent to which leg
pain limits a range of activities such as walking and
crossing the road (not limited to totally limited);
frequency of needing to stop walking (nil to >3x/day);
and the extent to which the respondent has thought
about, felt down about, worried about, had work
interference from, had interference with hobbies
and social activities from, and had interference doing
errands from leg pain (all the time to none of the
time). The questionnaire has acceptable test retest
reliability, internal consistency and construct validity
in people with intermittent claudication [83].
 Health-related quality of life will also be assessed
using the PAD Quality of Life (PADQoL), the EQ-
5D-5 L, and the SF36 (SF-36 v2) tools, which have
previously been identified as useful for people with
PAD [84–86]. The PADQoL has 38 items that ask
about PAD-related issues and experiences such as
activity restrictions; feelings of loss, vulnerability,
burden, hope, and confidence; and impact on work,
family and social activities. Responses are recorded
on a 6-point Likert scale with options ranging from
strongly agree to strongly disagree. The EQ-5D-5 L
is a descriptive system of health-related quality of
life states consisting of five dimensions (mobility,
self-care, usual activities, pain/discomfort, anxiety/
depression). The responses record five levels of
severity (no problems/slight problems/moderate
problems/severe problems/extreme problems) within
a particular EQ-5D dimension. The SF-36 has 36
items and assesses eight health concepts [87]:
limitations in physical activities because of health
problems; limitations in social activities because of
physical or emotional problems; limitations in usual
role activities because of physical health problems;
bodily pain; general mental health (psychological
distress and well-being); limitations in usual role
activities because of emotional problems; vitality
(energy and fatigue); and general health perceptions.
Two overall component scores can be derived to
reflect physical and mental health. Items assess
current functioning and during the past four weeks,
and responses are provided on Likert type scales
with three to five options.
To support an economic evaluation, cost information
will also be collected. The following direct health care
costs will be determined for every participant using data
collected as part of the case report form (CRF):
 The resources associated with the interventions
including the costs of training allied health
professionals, the cost of delivering the behavior
counselling intervention and the cost of monitoring
changes in physical activity; These costs include
both the salary cost of time spent by staff (pro rata,
including on-costs) for the intervention training,
implementation, and advisory sessions; administra-
tive costs (e.g., telephone calls), location costs
(rooms, utility costs), and travel costs of patients
(e.g., time and financial outlay).
 The health services resources used for
cardiovascular events will be assessed by data
collected on any hospital admissions during follow-
up including reason for admission, length of stay
and type of vascular intervention performed.
Overall, the cost of each participant’s continuous
inpatient stay (CIS) will be estimated using the
AR-DRG Grouper software licensed by Independent
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Hospital Pricing Authority (IHPA). This software
takes into account key variables that impact on a
patient’s CIS, such as principal and other diagnosis,
length of stay, age and sex.
 For each medication prescribed during follow-up
the associated costs will be estimated based on the
unit costs of prescriptions determined from finance/
purchasing department of the participating hospitals.
Some site-specific assessments will also be conducted
(See Additional file 2).
Data management and analyses
All study information will be stored securely at the study
site. All participant information will be stored in locked
cabinets in areas with limited access. All data will be iden-
tified by a coded identification number only to maintain
participant confidentiality. Records that contain names or
personal identifiers - such as case notes, consent forms or
appointment records - will be stored separately from re-
cords identified by code number. Trial documents includ-
ing study design, protocol, assessment manual, safety
reporting forms and case report forms (CRF) and neces-
sary software will be electronically shared with participat-
ing study centers.
Data recorded on printed CRFs will be scanned and
emailed to the trial coordinating center along with the
data file for the activPAL3™ accelerometer for assessment
of data quality and central data entry. Data from the CRFs
will be entered into a study database which incorporates
data validation rules to reduce transcription errors and
can only be accessed by authorised personnel. An extract
of the database will be examined regularly and checked by
the coordinating centre for data quality. Data entry is done
by staff blinded to participant allocation.
Data from the activPAL3™ will be analysed using the
manufacturer’s software (PAL Technologies Ltd, Glasgow,
United Kingdom) to derive measures of physical activity
and sedentary behavior. Data from the activPAL3™ will be
uploaded and visually inspected for anomalies. Participant
data will be considered valid if there is a minimum of 20 h
per day and 5 days of wear time. Default settings of the
activPAL3™ will be used to calculate 15-s epochs for each
variable using: a minimum sitting and/or upright period
of 10 s; a minimum walking cadence of 20 steps per
minute; and energy expenditure values of 1.25 MET for
sitting/lying, 1.4 MET for quiet standing, and 4 MET for
walking cadences of >119 steps per minute.
Between group differences in physical activity (primary
outcome) and other measures will be analysed using an
intention-to-treat approach and repeated measures mixed
models. All continuous data will be inspected for normality
of distribution visually and statistically, and non-normally
distributed data will be mathematically transformed if
possible prior to use with parametric statistics. Covariates
considered for use in these models include age, gender and
any characteristics significantly different between groups at
baseline which could potentially confound the variable of
interest in each model. Predictors of changes in primary
and secondary outcomes will be identified using simple and
multiple regression models of relevant baseline characteris-
tics (e.g., BMI and education). The incidence of revasculari-
sation in the intervention and usual care control groups
will be compared by chi-square test or logistic regression
adjusted for relevant baseline characteristics if needed.
Binomial logistic regression will be conducted to identify
factors that predict revascularisation. Differences in time to
revascularisation will be analysed by Kaplan Meier analysis
and log rank test. Given the low risk of the behavior
intervention planned in this study it is highly unlikely that
the trial would require stopping and thus no interim
analysis is planned. Relative effect sizes and 95 % Confi-
dence Intervals for primary and secondary outcomes will
be calculated. A p value of <0.05 will be accepted as statisti-
cally significant, given that all hypotheses to be tested have
been formulated a priori.
The base case economic evaluation will adopt the per-
spective of the health sector, meaning that the data analysis
will be restricted to including the costs and outcomes that
directly impact upon the health sector. Two forms of ana-
lysis will be undertaken: a cost-effectiveness analysis and a
cost-utility analysis. The cost-effectiveness analyses will
compare the direct costs of the intervention (minus any
cost savings) against the activity outcomes. An incremental
cost effectiveness ratio (ICER) will be calculated as follows:
ICER ¼ C1−C0ð Þ= E1−E0ð Þ
where C1 is the cost of the intervention (minus cost sav-
ings); C0 is the cost of the usual care; E1 is the effect
from the intervention; and E0 is the effect of the usual
care. C0 includes the costs associated with four separate
patient appointments, which comprises of a general
conversation, and on-going medical care. The difference
between C1 and C0 is the incremental or additional cost
being introduced to the health system. Similarly, the dif-
ference between E1 and E0 is the incremental effective-
ness of the intervention. Within a sensitivity analysis,
any working time lost will be converted into productivity
costs, thus widening the perspective of the analysis to in-
clude some societal costs.
From the information above, three cost-effectiveness
ICERs will be generated, as described below. For each
ICER, the incremental cost of the intervention will be
identical; whereas for effects, three activity outputs will
be used. This analysis will then generate: (i) cost per
additional 1000 steps/day walked; (ii) cost per additional
100 calories/day expended; and (iii) cost per additional
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minutes of moderate to vigorous intensity physical activ-
ity/day). This analysis will be performed at the 4-month
post intervention and 12 and 24 month follow-ups.
The cost-utility analyses will be then be undertaken. The
same direct costs will be included as before, however, in this
case, the outcome measure will be changed to quality-
adjusted life years (QALYs). Health utility scores will be
generated for each participant by converting responses to
HRQoL questionnaires into a single score using validated
algorithms. The algorithm weights responses to HRQoL
questions using population preferences and hence health
utility score are also known as (preference-weighted)
HRQoL. To estimate a quality-adjusted life year for cost-
utility analysis, we will convert the EQ-5D and SF-36 into
utility scores (the latter through the SF-6D) [88], and apply
Australian utility weights for each [89, 90]. This permits
cross-validation checks for the health utility values elicited
and exploration of the sensitivity of the incremental out-
come to choice of quality of life measure post-intervention.
These analyses will be performed at the 12 month and
24 month follow-up. In Australia, a new intervention is gen-
erally considered to be cost-effective if the ICER, the mean
cost per unitary change in mean utility is ≤ $50,000 [91, 92].
If the intervention is found to successfully improve health
outcomes, and to result in reduced time lost from work,
then the ‘perspective’ of the analysis would widen from the
health sector to incorporate productivity savings. For those
of working age, time lost from employment will be esti-
mated using the World Health Organization’s Health and
Performance Questionnaire (HPQ) [93]. Working time lost
will be converted to productivity losses by using average
Gross Domestic Product (GDP) per capita, adjusted pro
rata. If individuals are made unemployed (rather than tem-
porary sickness absence) then an assumption will be made
regarding the length of time before that position is replaced
by another person in the general population. A 90 fractional
day period will be assumed, before replacement takes place.
Any productivity losses would then be factored into the
value of C1 above (reducing it), and the ICERs would be
recalculated. This stage of the analysis would be reported
separately as these potential productivity savings do not fall
under the health care budget, and so is outside of the health
sector funder’s perspective.
Uncertainty analysis will be conducted by bootstrap-
ping patient level data and a value of information ana-
lysis (VOI) will estimate the need to undertake further
research to inform whether the intervention is value for
money [94]. All economic evaluation work will be imple-
mented using STATA and Microsoft Excel® (Microsoft
Corporation, Redmond, WA, USA).
Results will be disseminated via relevant scientific (e.g.,
journals, conferences), professional (e.g., newsletters),
and public (e.g., media) forums. There are no plans to
use professional writers.
Discussion
People with PAD constitute a high-risk population with
high rates of cardiovascular events and hospitalization; and
greater associated costs compared to patients presenting
with coronary artery disease alone [7]. Supervised exercise
programs can improve maximal walking distance, pain
symptoms and health-related quality of life [20, 28–31], but
have limited accessibility [32]. Unsupervised home- or
community-based exercise is a potentially attractive alterna-
tive to supervised exercise training, and can be effective in
increasing walking capacity, community-based walking, and
quality of life among people with PAD [28, 95, 96]. Com-
ponents of successful interventions to promote unsuper-
vised exercise in people with IC include self-monitoring,
goal setting, and problem solving barriers [96]. Behavioral
counselling typically includes these components, and there
is preliminary evidence that brief behavioral counselling by
a psychologist can promote sustained increases in walking
in people with PAD [53, 54], but the generalisability of this
to other health professionals is not known. In addition, little
is known about the impact of such programs on cardiovas-
cular disease risk [96].
This trial will test the efficacy and cost effectiveness of
brief behavioral counselling delivered by allied health
professionals in promoting physical activity and improv-
ing clinical outcomes in people with PAD. Using a range
of allied health professionals to deliver the counselling
across several settings will enhance wide scale applicabil-
ity if it proves effective. This brief intervention could
have a significant impact on PAD and how it is managed
in clinical settings, and represent a pragmatic means to
improve cardiovascular outcomes.
Trial status
At the time of manuscript submission (October 2016) this
study was ongoing. Recruitment and data collection com-
menced in Townsville in January 2015, and in Brisbane
and Sydney in September 2015, and was pending in Perth.
Trial sponsor
The Queensland Research Centre for Peripheral Vascular
Disease; College of Medicine and Dentistry, James Cook
University. Townsville QLD 4811, Australia.
Protocol version
At the time of submission, the trial was using protocol ver-
sion 5.3 (June 2016). Protocol amendments will be man-
aged and disseminated by the Trial Coordinating Centre.
Additional files
Additional file 1: PAD Information Sheet. (PDF 240 kb)
Additional file 2: Site Specific Additional Assessment. (PDF 177 kb)
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